Framework Programme 7

1
(No Transcript)
2
Framework Programme 7
3
Capacity
4
Capacity
5
Supporting Actions

• Activities in a Support action may cover
• Individual events conferences, seminars, working
  groups and expert groups Studies, analysis
• Fact findings and monitoring Preparatory
  technical work, including feasibility studies
  Development of research or innovation strategies
• High level scientific awards and competitions
• Operational support, data access and
  dissemination, information and communication
  activities
• (Support actions do not conduct ST research !)
• Experience of SSAs in FP6
• Average duration 9-30 months
• Optimum consortium 1-15 participants
• Total EC contribution 0.03-3 M

6
Coordination Actions

• Activities in a Coordination action may cover
• Networking, coordination and dissemination
  activities
• Management of the consortium
• (Coordination actions do not conduct ST research
  !)
• Experience of CAs in FP6
• Average duration 18-36 months
• Optimum consortium 13-26 participants
• Total EC contribution 0.5-2 M

7
Centar za funkcionalnu genomiku

• osnovan 2002 u svrhu promicanja translacijskih
  istraživanja kako bi se olakšala suradnja
  bazicnih i klinickih znanstvenika
• zajednicki projekt Medicinskog fakulteta,
  Klinickog bolnickog centra Zagreb i Harvard
  Medical School

8
Centar za funkcionalnu genomiku
9
Centar za funkcionalnu genomiku
10
Tehnologija

• Ekspresijsko profiliranje
• Chromatin Immunoprecipitation on Chip
  (ChIP-CHIP)
• Comparative Genomic Hybridization (CGH)
• SNP analysis using 500K Affymetrix microarrays
• Roche LightCycler real-time RT-PCR i klasicni
  PCR
• kultura stanica
• transfekcije primarnih kultura i stanicnih
  linija
• Western blotting, imunohistokemijske metode
• provjera kvalitete RNA pomocu Agilent Bioanalyzer

11
Projekti

• Krvni biomarkeri za Huntingtonovu bolest
• Krvni testovi za Parkinsonovu bolest
• Genomska analiza transkriptoma i interaktoma u
  bolesnika s kompleksnim bolestima
• Razvoj novih biomarkera za bolesnike sa
  shizofrenijom
• Dijegnostilki i prognosticki krvni markeri u
  bolesnika s multiplom sklerozom i retrobulbarnim
  neuritisom
• Molekularni mehanizmi osteoporoze
• Molekularna osnova CD34 pozitivnih akutnih
  mijeloidnih leukemija

12
Suradnja

• Harvard Medical School, Boston, USA
• Ludwig Maximilian University, Munich, Germany
• University of Tübingen, Tübingen, Germany
• Institute for Molecular Medicine, Lisabon,
  Portugal
• Tel-Aviv University, Tel-Aviv, Israel
• Medical Research Council Human Genetics Unit,
  Edinburgh, UK
• University of Edinburgh, Edinburgh, UK

13
Odabrana publikacije

• Cui L, Jeong H, Borovecki F, et al.
  Transcriptional repression of PGC-1alpha by
  mutant huntingtin leads to mitochondrial
  dysfunction and neurodegeneration. Cell.
  12759-69. 2006.
• Borovecki F, Lovrecic L, Zhou J, et al.
  Genome-wide expression profiling of human blood
  reveals biomarkers for Huntington's disease. Proc
  Natl Acad Sci U S A. 10211023-8. 2005.
• Paralkar VM, Borovecki F, Ke HZ, et al. An EP2
  receptor-selective prostaglandin E2 agonist
  induces bone healing. Proc Natl Acad Sci U S A.
  1006736-40. 2003.

14
Call identifier FP7-REGPOT-2007-1
Date of publication 22 December 2006 Deadline
24 April 2007, at 17 h, Brussels local
time Indicative budget 22 M
Activity/Area Topics called Funding Schemes
REGPOT-2007-1 Any research topic covered by the EC FP7 CSAs (Support Actions)
15
(No Transcript)
16
Detalji poziva
The FP7 Capacities Work Programme Research
Potential states under the specific topic
REGPOT-2007-1 This activity will give the
possibility to improve the research capacities of
highest quality and/or promising centres, in the
thematic priorities domains of the FP7, by
reinforcing their ST potential, by supporting
and mobilising the human and material resources,
by developing strategic partnerships (including
twinning) with well established research groups
elsewhere in the Union, by disseminating
scientific information as well as the results of
research, by facilitating communication between
the centres having similar scientific interest
and by improving their responses to
socio-economic needs of the country.
17
GRACE

• Genomic Research for Anthropology, Clinical
  medicine and Epidemiology (GRACE)
• Datum pripreme 03 ožujka 2005
• Vrsta projekta Specific Support Actions (SSA)

18
GRACE
19
INTEGERS

• INTEgrating and Strengthening GEnomic
• Research in South-Eastern Europe
• INTEGERS

20
INTEGERS
21
INTEGERS - Objectives

• strengthening and expanding the existing research
  infrastructure
• reinforcing the existing collaborations and
  knowledge transfer
• providing interested young researchers with
  employment opportunities
• dissemination of research results
• implementation of research results

22
INTEGERS WP1
23
INTEGERS WP2
24
INTEGERS WP3
25
INTEGERS WP4
26
INTEGERS WP4
27
INTEGERS WP5
28
Podnošenje projekta

• Tocno odredeno vrijeme
• 17h00 obicno utorkom, prema vremenu u Bruxelles-u
• Podnošenje jednim postupkom
• Elektronsko podnošenje prijedloga projekta
• EPSS (Electronic Proposal Submission System)

29
EPSS

• Svi prijedlozi projekta podnose se elektronski
  kroz Electronic Proposal Submission Service
  (EPSS)
• Part A ispunjava se on-line
• Part B unosi se u obliku PDF file-a sadrži
  detalje prijedloga projekta

30
Evaluacijski kriteriji

• Tri glavna kriterija
• ST Quality
• koncept, ciljevi, izvedbeni plan
• Implementation
• Opis sudionika projekat
• Raspodjela i korištenje sredstava
• Impact
• Doprinos predvidenim ucincima prema tekstu
  natjecaja
• Plan za diseminaciju/eksploataciju

31
Evaluacija
32
Evaluacija
33
(No Transcript)
34
Negotiation

• Potrebno dostaviti dodatne dokumente (o pravnom
  statusu ustanove, o bankovnom racunu)
• Dorada izvedbenog plana projekta (Annex I
  Description of Work, Grant Agreement Preparation
  Form GPF)
• Pregovori oko financijskih sredstava EK u
  pravilu smanjuje iznos traženih sredstava